Skip to main content
Contact Us
Subscribe
E-Edition
67°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
MoonLake Immunotherapeutics - Class A Ordinary Shares
(NQ:
MLTX
)
53.01
-1.30 (-2.39%)
Streaming Delayed Price
Updated: 11:39 AM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MoonLake Immunotherapeutics - Class A Ordinary Shares
< Previous
1
2
3
4
5
Next >
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
October 15, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
October 11, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
September 27, 2023
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.
Via
InvestorPlace
The Latest Analyst Ratings for MoonLake
September 18, 2023
Via
Benzinga
Expert Ratings for MoonLake
August 31, 2023
Via
Benzinga
10 Analysts Have This to Say About MoonLake
August 14, 2023
Via
Benzinga
Analyst Expectations for MoonLake's Future
July 26, 2023
Via
Benzinga
These 8 Stocks Are Outperforming Nvidia In 2023
September 18, 2023
Carvana has surged 1,001%, leading huge winners this year.
Via
Investor's Business Daily
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
September 12, 2023
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.
Via
Benzinga
Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday
September 12, 2023
A competitor's clinical trial stumble may be benefiting MoonLake.
Via
The Motley Fool
Where MoonLake Stands With Analysts
July 03, 2023
Via
Benzinga
Casey's General Stores, Cognyte Software, Beauty Health And Other Big Stocks Moving Higher On Tuesday
September 12, 2023
U.S. stocks traded lower, with the Dow Jones gaining around 90 points on Tuesday. Here are some big stocks recording gains in today’s session. Shengfeng Development Limited (NASDAQ: SFWL) shares jumped...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 19%
September 12, 2023
The companies are both working on treatments for a rare skin disease.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 12, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
September 11, 2023
Via
Benzinga
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
September 06, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
August 31, 2023
Via
Benzinga
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
August 31, 2023
Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
August 31, 2023
Via
Benzinga
The 7 Most Promising Momentum Stocks to Own Now
August 31, 2023
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.
Via
InvestorPlace
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 10, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
July 25, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
10 Short Squeeze Stocks To Watch: Baosheng Media, Toro Corp, Getty Images And More
July 18, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among...
Via
Benzinga
Price Target For MoonLake Doubled: Analyst Says Lead Program Has 'Best-In-Class Profile'
July 17, 2023
HC Wainwright has increased the price target for MoonLake Immunotherapeutics (NASDAQ: MLTX) from $37 to $75
Via
Benzinga
Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories
July 17, 2023
Benzinga
Via
Benzinga
MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022
July 17, 2023
MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for...
Via
Benzinga
10 Short Squeeze Stocks To Watch: Asset Entities, Lightning eMotors, Bullfrog AI, Carvana And More
July 10, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among...
Via
Benzinga
$40M Bet On MoonLake Immunotherapeutics? Check Out These 3 Stocks Insiders Are Buying
July 06, 2023
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 04, 2023
Via
Benzinga
10 Short Squeeze Stocks To Watch: A Leader That Moved Up 392 Positions, Intuitive Machines, Toro And More
July 03, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of new traders looking for the next huge move. High short interest and steep borrowing costs are among...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.